콘텐츠로 건너뛰기
Merck
모든 사진(1)

주요 문서

1604610

USP

Risedronate sodium

United States Pharmacopeia (USP) Reference Standard

동의어(들):

Risedronic acid monosodium salt hemi(pentahydrate)

로그인조직 및 계약 가격 보기


About This Item

실험식(Hill 표기법):
C7H10NNaO7P2 · 2.5H2O
CAS Number:
Molecular Weight:
350.13
MDL number:
UNSPSC 코드:
41116107
NACRES:
NA.24

Grade

pharmaceutical primary standard

API family

risedronate

제조업체/상표

USP

응용 분야

pharmaceutical (small molecule)

형식

neat

SMILES string

OP(C(P(O)([O-])=O)(O)CC1=CC=CN=C1)(O)=O.[Na+]

InChI

1S/2C7H11NO7P2.2Na.5H2O/c2*9-7(16(10,11)12,17(13,14)15)4-6-2-1-3-8-5-6;;;;;;;/h2*1-3,5,9H,4H2,(H2,10,11,12)(H2,13,14,15);;;5*1H2/q;;2*+1;;;;;/p-2

InChI key

HYFDYHPNTXOPPO-UHFFFAOYSA-L

유사한 제품을 찾으십니까? 방문 제품 비교 안내

일반 설명

Risedronate sodium is a member of the pyridinyl class of bisphosphonates. It is mostly used as an antiresorptive agent. It can be used in treating and preventing postmenopausal and glucocorticoid-induced osteoporosis.

애플리케이션

Risedronate sodium USP reference standard, intended for use in specified quality tests and assays as specified in the USP compendia. Also, for use with USP monographs such as:
  • Risedronate Sodium Tablets
  • Risedronate Sodium Delayed-Release Tablets

분석 메모

These products are for test and assay use only. They are not meant for administration to humans or animals and cannot be used to diagnose, treat, or cure diseases of any kind.  ​

기타 정보

Sales restrictions may apply.

픽토그램

Health hazardExclamation mark

신호어

Warning

유해 및 위험 성명서

Hazard Classifications

Acute Tox. 4 Oral - Eye Irrit. 2 - Repr. 2 - STOT SE 2

Storage Class Code

11 - Combustible Solids

WGK

WGK 3

Flash Point (°F)

Not applicable

Flash Point (°C)

Not applicable


가장 최신 버전 중 하나를 선택하세요:

시험 성적서(COA)

Lot/Batch Number

죄송합니다. 지금은 이 제품에 대한 COA이(가) 온라인에서 제공되지 않습니다.

도움이 필요하시면 연락하세요. 고객 지원 부서

이 제품을 이미 가지고 계십니까?

문서 라이브러리에서 최근에 구매한 제품에 대한 문서를 찾아보세요.

문서 라이브러리 방문

CUNHA F.
American Journal of Surgery, 76(3), 244-260 (1948)
Eliska Vaculikova et al.
Molecules (Basel, Switzerland), 19(11), 17848-17861 (2014-11-07)
One approach for the enhancement of oral drug bioavailability is the technique of nanoparticle preparation. Risedronate sodium (Biopharmaceutical Classification System Class III) was chosen as a model compound with high water solubility and low intestinal permeability. Eighteen samples of risedronate
Yoshihisa Hirota et al.
PloS one, 10(4), e0125737-e0125737 (2015-04-16)
UbiA prenyltransferase domain-containing protein 1 (UBIAD1) plays a significant role in vitamin K2 (MK-4) synthesis. We investigated the enzymological properties of UBIAD1 using microsomal fractions from Sf9 cells expressing UBIAD1 by analysing MK-4 biosynthetic activity. With regard to UBIAD1 enzyme
Jin Woo Park et al.
Archives of pharmacal research, 37(12), 1560-1569 (2013-11-21)
Risedronate is widely used clinically to treat osteoporosis, Paget's disease, hypercalcemia, bone metastasis, and multiple myeloma. However, its oral efficacy is restricted due to its low bioavailability and severe gastrointestinal adverse effects. This study was designed to evaluate the effect

자사의 과학자팀은 생명 과학, 재료 과학, 화학 합성, 크로마토그래피, 분석 및 기타 많은 영역을 포함한 모든 과학 분야에 경험이 있습니다..

고객지원팀으로 연락바랍니다.